Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Abroad (travel likely)Recruiting

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
Contact: Study coordinator (Wenjin Yin) · yinwenjin@renji.com · 86(21)68385569

Study leads

Wenjin Yin, M.D.
Principal Investigator
Renji Hospital,School of Medicine, Shanghai Jiaotong University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Berlin, Germany · Bremen, Germany

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Breast Cancer (Early Breast Cancer)

Abroad (travel likely)RecruitingPHASE2

Angers, France · Avignon, France

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

Colitis · Diarrhea · Malignant Genitourinary System Neoplasm

Abroad (travel likely)RecruitingPHASE1

Houston, United States

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

Advanced Breast Cancer

Abroad (travel likely)RecruitingPHASE2

St Louis, United States · East Providence, United States